FORM	4
------	---

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							. ,				. ,								
1. Name and Address of Reporting Person <sup>*</sup> Baity Glenn				A	2. Issuer Name and Ticker or Trading Symbol <u>ACADIA PHARMACEUTICALS INC</u> [ ACAD ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
				- [ A									X Officer	(give title		Other (s below)	pecify		
(Last)	(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year)							VP, GC & Sec.						
3911 SORRENTO VALLEY BLVD.					03	03/25/2011									,				
						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street)	EGO C	^	92121											ie) X Form 1	iled by One	Reno	orting Person	1	
		A	92121		_									Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(S	State)	(Zip)			Perso											0		
	(-	,								<u> </u>	<u> </u>	· -							
			ble I - Non	-					· /	Dis		,							
1. Title of Security (Instr. 3) Date (Month/					2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr.			I 5) Securitie Benefici Owned I	Beneficially Owned Following		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership					
								Code	v	Amount	t (A) or P			ported nsaction(s) str. 3 and 4)			(Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned         (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion Date		3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Da if any (Month/Day/Y		Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		e s ally g	Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)			
				C	Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Share	5	(Instr. 4)	1011(3)			
Stock option (right to buy)	\$1.62	03/25/2011			A		130,000		(1)		03/24/2021	Common Stock	130,00	0 \$0	130,0	00	D		

Explanation of Responses:

1. 25% of the shares subject to the Stock Option vest and become exercisable on March 25, 2012. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

/s/ Glenn F. Baity 03/29/2011

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.